Summit Therapeutics (SMMT) Receivables - Other (2017 - 2025)

Summit Therapeutics' (SMMT) quarterly Receivables - Other came in at $12000.0 in Q1 2025, down 86.67% on a QoQ basis from $90000.0 in Q3 2024.

Analysis

Summit Therapeutics (SMMT) Receivables - Other (2017 - 2025) Analysis & Trends

Summit Therapeutics (SMMT) has 7 years of Receivables - Other data on file, last reported at $12000.0 in Q1 2025.

Quarterly Receivables - Other changed N/A year-over-year to $12000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $12000.0 (changed N/A YoY) and the FY2021 annual result came in at $574000.0, changed N/A from the prior year.
Receivables - Other retreated to $12000.0 in Q1 2025, from $90000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $1.1 million in Q2 2022 to a low of $12000.0 in Q1 2025.
A 4-year average of $397833.3 and a median of $322500.0 in 2022 frame the typical range for Receivables - Other.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Summit Therapeutics	13.67 Bn	12.98 Bn	-

Historic Data

Download Data